Zacks Research Upgrades Medline (NASDAQ:MDLN) to Hold

Medline (NASDAQ:MDLN) was upgraded by analysts at Zacks Research to a “hold” rating in a research note issued on Tuesday,Zacks.com reports.

A number of other brokerages have also recently commented on MDLN. JPMorgan Chase & Co. assumed coverage on Medline in a research note on Monday. They issued an “overweight” rating and a $50.00 price target for the company. BNP Paribas Exane initiated coverage on Medline in a research note on Monday. They set a “neutral” rating and a $38.00 price target on the stock. Citigroup started coverage on Medline in a report on Monday. They set a “buy” rating and a $48.00 price target on the stock. The Goldman Sachs Group started coverage on shares of Medline in a research report on Monday. They set a “buy” rating and a $49.00 target price on the stock. Finally, Royal Bank Of Canada began coverage on shares of Medline in a report on Monday. They set an “outperform” rating and a $47.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat, Medline currently has an average rating of “Moderate Buy” and an average price target of $46.70.

Medline Stock Performance

Shares of Medline stock opened at $43.41 on Tuesday. Medline has a 1 year low of $34.89 and a 1 year high of $45.50.

Insider Transactions at Medline

In other news, Director Andrew J. Mills purchased 2,586,206 shares of the business’s stock in a transaction on Thursday, December 18th. The shares were acquired at an average price of $29.00 per share, with a total value of $74,999,974.00. Following the completion of the transaction, the director owned 2,586,206 shares of the company’s stock, valued at $74,999,974. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of the stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $28.37, for a total value of $172,727,085.27. Following the sale, the insider owned 4,806,160 shares of the company’s stock, valued at approximately $136,350,759.20. The trade was a 55.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure.

Key Stories Impacting Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Medline raised roughly $7.2 billion in its IPO and analysts quickly launched coverage, which is supporting buying interest and secondary market liquidity. Medline Shares Climb as Analysts Launch Coverage After $7.2 Billion IPO
• Positive Sentiment: UBS initiated coverage with a “buy” rating and a $48 price target (about a mid‑teens upside from current levels), giving investors a clear upside case and a visible benchmark for valuation. UBS coverage (reported)
• Positive Sentiment: Multiple major banks (JPMorgan, Citigroup, Barclays, Wells Fargo, Jefferies, Deutsche Bank, TD Cowen, Mizuho, Wolfe Research, Rothschild/Redburn and others) have initiated coverage over the last 24 hours — broad analyst interest typically improves discoverability and can attract institutional orders. JPMorgan coverage (example)
• Neutral Sentiment: Market commentary highlights MDLN as a fresh IPO for long‑term investors, but notes that early post‑IPO performance depends on execution and margin trends rather than headline demand alone. MarketBeat feature
• Neutral Sentiment: BNP Paribas has a “hold” rating — not a sell signal, but a reminder some analysts view near‑term upside as limited until Medline proves post‑IPO execution and growth targets. BNP Paribas hold (reported)

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.